The risk of atrial fibrillation with ibrutinib use: A systematic review and meta-analysis

Blood

Volumn 128, Issue 1, 2016, Pages 138-140

  Leong, Darryl P ^a   Caron, François ^a   Hillis, Christopher ^a   Duan, Annie ^a   Healey, Jeff S ^a   Fraser, Graeme ^a   Siegal, Deborah ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; IBRUTINIB; OFATUMUMAB; PLACEBO; RITUXIMAB; TEMSIROLIMUS; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ATRIAL FIBRILLATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LETTER; LYMPHOCYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL LYMPHOCYTIC LYMPHOMA; SYSTEMATIC REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; INCIDENCE; LEUKEMIA; LYMPHOMA;

ANIMALS; ATRIAL FIBRILLATION; HUMANS; INCIDENCE; LEUKEMIA; LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84982147026     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-05-712828     Document Type: Letter

References (25)

1. Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-2437.
2. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
3. Chanan-Khan A, Cramer P, Demirkan F, et al; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
4. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770-778.
5. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.
6. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279.
7. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
8. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib therapy in rituximab-refractory patients with Waldenström's macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE™) [abstract]. Blood. 2015;126(23). Abstract 2745.
9. Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A. Atrial fibrillation in CLL/SLL patients on ibrutinib [abstract]. Blood. 2015;126(23). Abstract 2933.
10. Fowler N, Nastoupil L, De Vos S, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study [abstract]. Blood. 2015;126(23). Abstract 470.
11. O'Brien S, Coutre S, Furman RR, et al. Durable responses including complete responses in CLL following long term treatment with single-agent ibrutinib 420 mg [abstract]. Clin Lymphoma Myeloma Leuk. 2015;15(suppl 2):S23. Abstract 300.
12. Stilgenbauer S, Jones JA, Coutre SE, et al. Results from the phase 2 RESONATETM-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p [abstract]. Oncol Res Treat. 2015;38(suppl 5):92. Abstract V291.
13. Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842-850.
14. Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48-56.
15. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739-745.
16. Parikh SA, Chaffee KR, Call TG, et al. Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice [abstract]. Blood. 2015;126(23). Abstract 2935.
17. Sandoval-Sus JD, Chavez JC, Dalia S, et al. Outcomes of patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience [abstract]. Blood. 2015;126(23). Abstract 2945.
18. Romisher A, Carver J, Schuster SJ, et al. Bruton's tyrosine kinase inhibition is associated with manageable cardiac toxicity [abstract]. Blood. 2015;126(23). Abstract 4529.
19. Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175-1179.
20. Hansson L, Winqvist M, Asklid A, et al. Real-world results on ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Data from 97 Swedish patients treated in a compassionate use program [abstract]. Blood. 2015;126(23). Abstract 1745.
21. Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016;91(6):E312-E313.
22. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-953.
23. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455-2461.
24. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829-3830.
25. Ekman N, Lymboussaki A, Västrik I, Sarvas K, Kaipainen A, Alitalo K. Bmx tyrosine kinase is specifically expressed in the endocardium and the endothelium of large arteries. Circulation. 1997;96(6):1729-1732.